Home > Boards > US OTC > Medical - Drugs > PHARMA MAR (PHMMF)

PharmaMar presents results of trabectedin & doxorubicin for

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
radly Member Profile
 
Followed By 13
Posts 2,357
Boards Moderated 0
Alias Born 01/11/12
160x600 placeholder
radly   Monday, 06/01/20 11:35:23 AM
Re: None
Post # of 51 
PharmaMar presents results of trabectedin & doxorubicin for first line treatment of leiomyosarcomas at ASCO 2020
Madrid, June 1st, 2020.- PharmaMar (MSE:PHM) has announced that the final results from the Phase II study of trabectedin in combination with doxorubicin for the treatment of patients with advanced metastatic uterine and soft tissue leiomyosarcoma have been presented in an Oral Abstract Session at the American Society of Clinical Oncology (ASCO) Annual Meeting, that was held on May 29th to 31st, 2020.

Under the title "A single-arm multicenter phase II trial of doxorubicin (Doxo) in combination with trabectedin (Trab) given as first-line treatment to patients with metastatic/advanced uterine (U-LMS) and soft tissue leiomyosarcoma (ST-LMS): Final results of the LMS-02 study" (Abstract 11506), Patricia Pautier, MD, from the Medical Oncology Department, Institut Gustave Roussy, Villejuif, France, has concluded that trabectedin in combination with doxorubicin is an effective first-line treatment for patients with leiomyosarcoma.

The study achieved its primary and secondary endpoints, with a median Progression-Free Survival (PFS) of 10.1 months; a median Overall Survival (OS) of 34.4 months and an acceptable safety profile.

As a reference (not comparable head-to-head studies), the most recent results of other doxorubicin combinations, such as those presented in ASCO 2019 in the “ANNOUNCE” Phase III study (doxorubicin + olaratumumab), reported a median PFS of 6.9 months, and an OS of 21.9 months (ASCO 2019 LBA3)[1].

Patricia Pautier, MD, said: "Combination of doxorubicin and trabectedin constitutes an active first-line therapy for patients with uterine and soft tissue leiomyosarcoma. Results in overall response rate, progression free survival and now in overall survival are very encouraging.” And added: “Results of the LMS04 trial, a randomized phase-III study comparing this combination followed by trabectedin versus doxorubicin alone in 1st-line therapy in metastatic LMS are pending.”

All virtual ASCO poster presentations will be available on request to registered participants for 180 days from May 29th, 2020: https://meetinglibrary.asco.org


Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences